Yen Wen Yu
Förmögenhet: 4 M $ per 2026-09-30
Förmögenhet: 4 M $ per 2026-09-30
Mr. Yen Wen Yu is a Chief Operating Officer at Disc Medicine, Inc. Mr. Yu was previously employed as a Vice President-Finance & Operations by Qpex Biopharma, Inc. and a VP-Strategic Planning & Corporate Development by The Medicines Co. He received his undergraduate degree from Harvard College and an MBA from The Wharton School of the University of Pennsylvania.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
DISC MEDICINE, INC. 0,14 % | 2026-08-25 | 54 324 ( 0,14 % ) | 4 M $ | 2026-09-30 |
| Företag | Position | Start |
|---|---|---|
| DISC MEDICINE, INC. | Verksamhetschef | 2024-02-07 |
| Företag | Position | Slut |
|---|---|---|
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Grundare | 2020-07-01 |
| THE MEDICINES COMPANY | Företagsledare/Principal | 2018-07-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån